Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5501–5550 of 18644
appointed Elizabeth E. McShane to serve as our Chief Financial Officer, Treasurer and Secretary, effective as of May 20, 2024.
Zackery A. Weber, our current Vice President of Finance and principal financial and accounting officer, informed us of his intent to resign from all positions with the Company, effective June 3, 2024, citing 'good reason.'
appointed Paul Kosturos as interim Chief Financial Officer of the Company, effective May 6, 2024
Mr. Kosturos succeeds Eric Tiziani, who resigned from his role as Chief Financial Officer of the Company, effective May 6, 2024
The Board designated Mr. McCarthy as interim principal executive officer, effective as of May 1, 2024, for purposes of the rules and regulations of the Securities Exchange Commission.
Robert M. Bakish stepped down as Paramount Global's President and Chief Executive Officer and has resigned from the Board, in each case, effective as of the end of the day on April 30, 2024.
the previously disclosed retirement of Richard J. Wehrle as Executive Vice President, Chief Financial Officer and Treasurer
On April 29, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Ms. Nancy Smith, the Company’s Director of Internal Audit, to Interim Chief Financial Officer of the Company, effective immediately.
As previously announced, on the Retirement Date, Jeremy B. Ford, the Company’s current President and Chief Executive Officer became PlainsCapital Bank’s Chief Executive Officer.
retire from his roles as President and Chief Executive Officer by the end of the current calendar year, after the appointment of a successor.
Resignation of Nik Singhal as Director and Chief Executive Officer of the Company
pursuant to and in connection with the Merger, Joseph Kim (President, Chief Executive Officer), Dylan A. Bramhall (Chief Financial Officer), Christopher R. Curia (Executive Vice President, Human Resources), Karl R. Fails (Chief Operating Officer), Scott Grischow (Senior Vice President, Finance and Treasurer), Brian A. Hand (Chief Sales Officer), Austin Harkness (Executive Vice President, Commercial), Peggy Harrison (Assistant Secretary), Robert M. Kerrigan III (Senior Vice President, Human Resources & Administration), Darryl Krebs (Vice President, Tax)
pursuant to and in connection with the Merger, Joseph Kim (President, Chief Executive Officer), Dylan A. Bramhall (Chief Financial Officer), Christopher R. Curia (Executive Vice President, Human Resources), Karl R. Fails (Chief Operating Officer), Scott Grischow (Senior Vice President, Finance and Treasurer), Brian A. Hand (Chief Sales Officer), Austin Harkness (Executive Vice President, Commercial), Peggy Harrison (Assistant Secretary), Robert M. Kerrigan III (Senior Vice President, Human Resources & Administration), Darryl Krebs (Vice President, Tax)
Peter Vlerick tendered his resignation as Chief Financial Officer of the Company on March 8, 2024 (after close of the ASX), which became effective as of May 3, 2024.
At the Effective Time of the Merger, all of the directors and executive officers of Summit ceased serving as directors and executive officers of Summit.
At the Effective Time of the Merger, all of the directors and executive officers of Summit ceased serving as directors and executive officers of Summit.
On April 30, 2024, the board of directors of BioSig Technologies, Inc. (the “Board”) appointed former advisory board member and consultant, Anthony Amato as a director, president, chief executive officer and principal executive officer, effective immediately.
In connection with the appointment of Mr. Amato, Mr. Hrkac tendered his resignation as president and principal executive officer effective as of the same date, however, will continue to serve as a director and acting chief financial officer.
As of such date, A. Hadi Chaudhry is no longer President of the Registrant, but remains the Registrant’s Chief Executive Officer.
Effective April 30, 2024, Monica Diaz Brickell left the Company, including her position as the Chief Financial Officer of the Company.
appointed Jeff Brown, Chief Operating Officer of the Company, as Chief Financial Officer and Chief Operating Officer of the Company, effective as of May 1, 2024.
The Company has appointed David Afshar as interim principal financial officer and principal accounting officer of the Company.
On April 29, 2024, David H. Gould (the "Resigning Officer"), principal financial officer and principal accounting officer of American Oncology Network, Inc. (the "Company") notified the Company of his intention to resign as principal financial officer and principal accounting officer of the Company, effective May 17, 2024.
On May 1, 2024, the Board of Directors of the Company appointed Dennis Fehr as Senior Vice President of Finance and Chief Financial Officer of the Company, effective May 3, 2024.
Joseph Schachinger, as previously announced, has succeeded Anthony McKiernan as Chief Financial Officer of the Company as of April 30, 2024, and will no longer serve as the Company’s principal accounting officer as of the date of Ms. Yu’s appointment.
Anant Bhalla ceased to be an executive officer of the Company as of the Effective Time.
Matthew Smith, who will continue in his role as Chief Financial Officer, will no longer serve as the principal accounting officer.
and has appointed Joel Arnao, the Company’s current Senior Vice President, FP&A, Treasury, and Investor Relations, as the Company’s interim Chief Financial Officer
On April 26, 2024, Gary W. Ferrera, the Company’s Executive Vice President and Chief Financial Officer, notified the Company of his intent to resign from the Company to pursue a professional opportunity at a privately held company.
On April 26, 2024, William G. Kachioff notified Eiger BioPharmaceuticals, Inc. (the “ Company ”) of his resignation as the Company’s Chief Financial Officer, to be effective April 29, 2024.
submitted his resignation as CEO, effective August 1, 2024
the Board appointed Margaret ("Margi") Tooth, the Company's President, as the CEO, to be effective as of August 1, 2024.
each of Douglas Baum, QSAM's Chief Executive Officer, C. Richard Piazza, QSAM's Executive chairman, Adam King, QSAM's Chief Financial Officer, and Christopher Nelson, QSAM's General Counsel, ceased to be an executive officer
each of Douglas Baum, QSAM's Chief Executive Officer, C. Richard Piazza, QSAM's Executive chairman, Adam King, QSAM's Chief Financial Officer, and Christopher Nelson, QSAM's General Counsel, ceased to be an executive officer
the Board of Directors of the Company appointed William R. “Russ” Colvin as the Company’s President, Chief Executive Officer, and Director of the Company.
On May 2, 2024, the Company announced that Glynis Bryan intends to retire as Chief Financial Officer of Insight Enterprises, Inc. (the “Company”), effective December 31, 2024.
Effective as of the close of business on May 2, 2024, Mr. McCarthy will transition from President and Chief Executive Officer (“CEO”) of the Company to a non-executive, strategic advisory role.
On May 2, 2024, the Company announced that Karen Boone, current Chairperson of the Board, and Chris Bruzzo, a Board director, have been appointed as Interim Co-CEOs and co-Presidents of the Company, and that Jay Hoag, a Board director, has been named Chairperson of the Board, effective May 2, 2024.
On May 2, 2024, the Company announced that Karen Boone, current Chairperson of the Board, and Chris Bruzzo, a Board director, have been appointed as Interim Co-CEOs and co-Presidents of the Company, and that Jay Hoag, a Board director, has been named Chairperson of the Board, effective May 2, 2024.
Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024
Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024
Tarak Mehta would be appointed CEO on September 5, 2024
Richard G. Kyle, President and Chief Executive Officer (“CEO”) of the Company would be retiring from his position as CEO
The Board appointed Padraig McDonnell as CEO of the Company and as a member of the Company’s Board.
On May 1, 2024, Mr. McMullen retired as President and CEO of the Company and as a member of the Company’s Board.
Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.
the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024
On April 26, 2024, the Board of Directors (the “ Board ”) of Journey Medical Corporation (the “ Company ”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer.
On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.
Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.